Latest News-CliniExpert

Galidesivir Stops Zika Viral Replication in Primate Model

RESEARCH TRIANGLE PARK, N.C., June 10, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data published in Science Translational Medicine show, in a primate mod

Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis

NEW YORK--(BUSINESS WIRE) June 10, 2020 -- Pfizer Inc. (NYSE: PFE) announced today positive top-line results from the Phase 3 JADE TEEN study of abrocitinib, an investigational oral once-daily Janus k

RedHill Biopharma Submits COVID-19 Clinical Trial Application for Phase 2/3 Study with Opaganib

TEL-AVIV, Israel and RALEIGH, NC, June 10, 2020 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it has submitted a Cl

Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate; Phase 1/2a Clinical Trial to Begin in Second Half of July

NEW BRUNSWICK, N.J., June 10, 2020 -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of t

First Patient Dose Delivered for Lilly's Tirzepatide Cardiovascular Outcomes Trial

INDIANAPOLIS, June 9, 2020 /PRNewswire/ -- The first patient dose has been delivered in SURPASS-CVOT, the phase 3 cardiovascular outcomes trial for tirzepatide, Eli Lilly and Company's (NYSE: LLY)

Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment

INDIANAPOLIS, June 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today its partner Junshi Biosciences (HKEX: 1877) has dosed the first healthy volunteer in a study of a potential

Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES Study of Anemia in Non-Dialysis-Dependent Adult Patients with Chronic Kidney Disease

TOKYO, June 8, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced results from the Phase 3 DOLOMITES study, evaluatin

Alnylam Presents Positive Phase 3 Results from ILLUMINATE-A Study of Lumasiran, an Investigational RNAi Therapeutic for Treatment of Primary Hyperoxaluria Type 1

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 7, 2020 -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive Phase 3 results from the ILLUMINATE-A s

Calquence Showed Promising Clinical Improvement in Majority of 19 Hospitalised COVID-19 Patients

June 5, 2020 -- Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved clinical outcome

The University of Queensland, CEPI and CSL Partner to Advance Development and Manufacture of COVID-19 Vaccine Candidate

June 5, 2020, Oslo, Melbourne and Brisbane -- CEPI, the Coalition for Epidemic Preparedness Innovations, CSL (ASX:CSL) and The University of Queensland (UQ) today announced that they have entered into

GSK Announces New Data Presentations from the DREAMM Programme Exploring Investigational Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma

04 June 2020 -- GlaxoSmithKline (GSK) plc today announced new data from its DREAMM (DRiving Excellence in Approaches to Multiple Myeloma) clinical trial programme of belantamab mafodotin in relapsed/r

AstraZeneca Takes Next Steps Towards Broad and Equitable Access to Oxford University’s COVID-19 Vaccine

4 June 2020 -- AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, following landmark agreements with the Coalit